Alirocumab is a monoclonal antibody that primarily functions as a PCSK9 inhibitor, which plays a crucial role in regulating cholesterol levels in the bloodstream. It is designed to target and bind to the proprotein convertase subtilisin/kexin type 9 (PCSK9) protein, preventing it from degrading LDL receptors on liver cells. This action enhances the liver's ability to remove low-density lipoprotein (LDL) cholesterol from the blood, thereby lowering overall cholesterol levels. Alirocumab is administered via subcutaneous injection and is typically used in conjunction with diet and other lipid-lowering therapies for patients with hyperlipidemia, particularly those who are at high cardiovascular risk. The drug is characterized by its specificity, high affinity for PCSK9, and a long half-life, allowing for less frequent dosing. Common side effects may include injection site reactions, flu-like symptoms, and allergic reactions. As a biologic agent, alirocumab represents a significant advancement in the treatment of cholesterol-related conditions, offering an alternative for patients who are intolerant to statins or require additional LDL cholesterol reduction.

Alirocumab

1245916-14-6: Alirocumab is a monoclonal antibody that primarily functions as a PCSK9 inhibitor, which plays a crucial role in regulating cholesterol levels in the bloodstream. It is designed to target and bind to the proprotein convertase subtilisin/kexin type 9 (PCSK9) protein, preventing it from degrading LDL receptors on liver cells. This action enhances the liver's ability to remove low-density lipoprotein (LDL) cholesterol from the blood, thereby lowering overall cholesterol levels. Alirocumab is administered via subcutaneous injection and is typically used in conjunction with diet and other lipid-lowering therapies for patients with hyperlipidemia, particularly those who are at high cardiovascular risk. The drug is characterized by its specificity, high affinity for PCSK9, and a long half-life, allowing for less frequent dosing. Common side effects may include injection site reactions, flu-like symptoms, and allergic reactions. As a biologic agent, alirocumab represents a significant advancement in the treatment of cholesterol-related conditions, offering an alternative for patients who are intolerant to statins or require additional LDL cholesterol reduction.

Alirocumab is a human monoclonal antibody that inhibits PCSK9. It is produced by recombinant DNA technology in Chinese hamster ovary cell suspension culture.

<p>Monoclonal antibody to PCSK9 ; inhibitor of proprotein convertase PCSK9</p>

CAS 1245916-14-6

Alirocumab

Alirocumab

Ref: IN-DA009JQY

Alirocumab

Ref: TM-T9916

Alirocumab

Ref: 3D-BA165582